Results of using L-ornitin-L-aspartate in the treatment of hepatic encephalopathy in liver transplantation
Open Access
- 21 September 2021
- journal article
- Published by IPO Association of Transplantologists in Transplantologiya
- Vol. 13 (3), 235-247
- https://doi.org/10.23873/2074-0506-2021-13-3-235-247
Abstract
The aim was to study the results of using various treatment regimens for hepatic encephalopathy for patients with liver cirrhosis before and after liver transplantation and the effect on the incidence and severity of hepatic encephalopathy in the perioperative period, and on the posttransplantation course.Material and methods. Fifty four patients with cirrhosis of various etiologies and the presence of significant hepatic encephalopathy undergoing living donor liver transplantation were included in the study. In the comparison group, patients took lactulose and rifaximin. In the main group, patients took lactulose and rifaximin in combination with L-ornithine-L-aspartate in the preoperative period, and L-ornithine-L-aspartate after liver transplantation for 5 days.Results. The use of L-ornithine-L-aspartate in the complex therapy of hepatic encephalopathy led to significantly reduced time of performing the Number Connection Test, the improvement of cognitive functions in patients by the Montreal Cognitive Assessment, a decreased incidence of stage II–III hepatic encephalopathy and an increased incidence of stage 0-I hepatic encephalopathy in the preoperative period. In the postoperative period, patients of the main group showed a rapid decrease in the severe stages of hepatic encephalopathy (stage II–III) towards less severe forms (stage 0–I) on the 3rd, 5th and 7th days after liver transplantation, and also a faster recovery of cognitive functions, an earlier adequate recovery of consciousness, muscle tone, an earlier possibility of extubation, a shorter length of stay in the intensive care unit, and a decreased postoperative hospital length of stay relatively to the patients of the comparison group.Conclusion. The use of L-ornithine-L-aspartate in the combination therapy for hepatic encephalopathy in the peritransplantation period leads to a significant decrease of the incidence and severity of hepatic encephalopathy, accelerates rehabilitation of patients, reduces postoperative hospital length of stay.Keywords
This publication has 21 references indexed in Scilit:
- Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic OptionsJournal of Clinical and Translational Hepatology, 2017
- Liver Transplantation for Unresectable Hepatic Alveolar EchinococcosisSovremennye tehnologii v medicine, 2017
- Hepatic encephalopathy expands the predictivity of model for end‐stage liver disease in liver transplant setting: Evidence by means of 2 independent cohortsLiver Transplantation, 2016
- Evaluation and Management of Hepatic Encephalopathy: Current Status and Future DirectionsGut and Liver, 2016
- Comparative results of use liver protecting drugs for prophylaxis of the liver failure after extensive resections of the liverKhirurgiya. Zhurnal im. N.I. Pirogova, 2016
- Covert and Overt Hepatic Encephalopathy: Diagnosis and ManagementClinical Gastroenterology and Hepatology, 2015
- Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the LiverJournal of Hepatology, 2014
- Management of Hepatic Encephalopathy in the HospitalMayo Clinic Proceedings, 2014
- The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive ImpairmentJournal of the American Geriatrics Society, 2005
- Hepatic encephalopathy-Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998Journal of Hepatology, 2002